Press releases
- BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
- BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region
- BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
- BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
- BeiGene Reports First Quarter 2024 Financial Results and Business Updates
- BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
- Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
- BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
More ▼
Key statistics
As of last trade, Beigene Ltd (49BA:DUS) traded at 132.00, 11.86% above the 52 week low of 118.00 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 131.00 |
---|---|
High | 132.00 |
Low | 131.00 |
Bid | 132.00 |
Offer | 136.00 |
Previous close | 134.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 105.81m |
Free float | 104.10m |
P/E (TTM) | -- |
Market cap | 15.63bn USD |
EPS (TTM) | -7.57 USD |
Data delayed at least 15 minutes, as of Jul 09 2024 08:32 BST.
More ▼